Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial von Smith, Matthew R, Scher, Howard I, Sandhu, Shahneen, Efstathiou, Eleni, Lara, Primo N, Yu, Evan Y, Chi, Kim N, Ståhl, Olof, Olmos, David, Danila, Daniel C, Espina, Byron M, Zhao, Xin, Urtishak, Karen A, Francis, Peter, Lopez-Gitlitz, Angela, Parnis, Francis, Horvath, Lisa G., Steer, Christopher, Marx, Gavin, Sandhu, Shahneen, Ferguson, Thomas, Luyten, Daisy, Lumen, Nicolaas, Dirix, Luc, Goeminne, Jean-Charles, Gil, Thierry, Vulsteke, Christof, Kussumoto, Celio, Franke, Fabio A., Martinelli de Oliveira, Fabricio Augusto, Pereira de Santana Gomes, Andrea Juliana, Preto, Daniel D'Almeida, Zucca, Luis Eduardo, Borges, Giuliano Santos, Murad, Andre M., Saad, Fred, Chi, Kim N., Fradet, Yves, Fleshner, Neil E., Emmenegger, Urban, Brasso, Klaus, Culine, Stephane, Thiery-Vuillemin, Antoine, Joly, Florence, Fléchon, Aude, Hilgers, Werner, Borchiellini, Delphine, Barthélémy, Philippe, Berger, Raanan, Mermershtain, Wilmosh, Peer, Avivit, Sella, Avishay, Voortman, Johannes, Aarts, Maureen J., Gietema, Jourik A., Choi, Young-Deuk, Gafanov, Rustem A., Kopyltsov, Evgeniy, Carles, Joan, Mellado, Begoña, Maroto, José Pablo, García-Donás, Jesús, Rodríguez Moreno, Juan Francisco, Durán, Ignacio, Pérez-Valderrama, Begoña, Castro, Elena, Olmos, David, Méndez-Vidal, María José, Muñoz-Langa, José, Herranz, Urbano Anido, Puente Vázquez, Javier, Castellanos, Enrique, Hellström, Martin, Widmark, Anders, Lissbrant, Ingela Franck, Jellvert, Åsa, Külich, Cecilia, Blom, René, Kang, Chih-Hsiung, Ou, Yen-Chuan, Wang, Shian-Shiang, Attard, Gerhardt, Bahl, Amit, Kellati, Prasad, Parikh, Omi, Srinivasan, Rajaguru, Lester, Jason F., Staffurth, John N., Cheng, Heather H., Efstathiou, Eleni, Pilié, Patrick G., George, Daniel J., Karsh, Lawrence I., Kelly, W. Kevin, Danila, Daniel C., Smith, Matthew R., Heath, Elisabeth I., Vaishampayan, Ulka N., Emamekhoo, Hamid, Pinski, Jacek K.

Volltext

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma von McDermott, David F, Lee, Jae-Lyun, Bjarnason, Georg A, Larkin, James M G, Gafanov, Rustem A, Kochenderfer, Mark D, Jensen, Niels Viggo, Donskov, Frede, Malik, Jahangeer, Poprach, Alexandr, Tykodi, Scott S, Alonso-Gordoa, Teresa, Cho, Daniel C, Geertsen, Poul F, Climent Duran, Miguel Angel, DiSimone, Christopher, Silverman, Rachel Kloss, Perini, Rodolfo F, Schloss, Charles, Atkins, Michael B

Volltext

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, doubl... von Tomczak, Piotr, Venugopal, Balaji, Ferguson, Thomas, Chang, Yen-Hwa, Gross-Goupil, Marine, Burgents, Joseph E, Xu, Lei, Imai, Kentaro, Choueiri, Toni K, Venugopal, Balaji, Lin, Tzu-Ping, Symeonides, Stefan N., Sawrycki, Piotr, Haas, Naomi B., Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Doshi, Gurjyot, Melichar, Bohuslav, Kopyltsov, Evgeniy, Hammers, Hans-Joerg, Menezes, Juliana de Janoski, Winquist, Eric W., Hamzaj, Alketa, Karaszewska, Boguslawa, Lipatov, Oleg N., McDermott, David, Kochuparambil, Samith T., Davis, Ian D., Peltola, Katriina, Sabbatini, Roberto, Shkolnik, Michail I., McCune, Steven, Yeung, Carrie, Laguerre, Brigitte, Fomin, Eugeniy A., Zakharia, Yousef, Yorio, Jeffrey T., Yanez Ruiz, Eduardo, Kimura, Go, Nishimura, Kazuo, Masumori, Naoya, Kato, Haruaki, Sala Gonzalez, Nuria, Chiu, Kun-Yuan, Atkins, Michael B., Heath, Elisabeth, Feyerabend, Susan, Numakura, Kazuyuki, Zukov, Ruslan, Maroto Rey, Pablo Jose, Chang, Chao-Hsiang, Vengalil, Salil, Waddell, Tom S., Hauke, Ralph, Jayram, Gautam, Estay, Angela, Rubiano, Juan Andres, Anai, Satoshi, Tsunemori, Hiroyuki, Sikora-Kupis, Bozena, Gunderson, Elizabeth, Koletsky, Alan, Chen, Kevin, Agrawal, Manish, Parnis, Francis, Barbosa, Fernando Maciel, Faucher, Genevieve, Iqbal, Nayyer, Hanna, Nawar, Ibanez, Carolina, Manneh, Ray, Holeckova, Petra, Ronkainen, Hanna, Abadie-Lacourtoisie, Sophie, Goebell, Peter J., Hoefner, Thomas, Schultze-Seemann, Wolfgang, Yokomizo, Akira, Matsukawa, Yoshihisa, Murakami, Yoji, Kim, Miso, Szczylik, Cezary, Humphreys, Alison C., Kumar, Birendra, Karam, Jose Antonio, Fleming, Mark, Zarba, Juan Jose, Leiva, Viviana E., Antonio Junior, Joao Neif, Rocha, Roberto Odebrecht, Muniz, David, Brust, Leandro, Graham, Jeffrey, Borchiellini, Delphine, McDermott, Ray, Miura, Yuji, Prow, Debra M., Hashemi-Sadraei, Neda, Kendall, Stephan D.

Volltext

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma von Rini, Brian I, Plimack, Elizabeth R, Stus, Viktor, Gafanov, Rustem, Hawkins, Robert, Nosov, Dmitry, Pouliot, Frédéric, Alekseev, Boris, Soulières, Denis, Melichar, Bohuslav, Vynnychenko, Ihor, Kryzhanivska, Anna, Bondarenko, Igor, Azevedo, Sergio J, Borchiellini, Delphine, Szczylik, Cezary, Markus, Maurice, McDermott, Raymond S, Bedke, Jens, Tartas, Sophie, Chang, Yen-Hwa, Tamada, Satoshi, Shou, Qiong, Perini, Rodolfo F, Chen, Mei, Atkins, Michael B, Powles, Thomas

Volltext

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, p... von Powles, Thomas, Plimack, Elizabeth R, Soulières, Denis, Waddell, Tom, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Pouliot, Frédéric, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio J, Borchiellini, Delphine, McDermott, Raymond S, Bedke, Jens, Tamada, Satoshi, Yin, Lina, Chen, Mei, Molife, L Rhoda, Atkins, Michael B, Rini, Brian I

Volltext

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma von McDermott, David F, Lee, Jae-Lyun, Ziobro, Marek, Suarez, Cristina, Langiewicz, Przemyslaw, Matveev, Vsevolod Borisovich, Wiechno, Pawel, Gafanov, Rustem Airatovich, Tomczak, Piotr, Pouliot, Frederic, Donskov, Frede, Alekseev, Boris Yakovlevich, Shin, Sang Joon, Bjarnason, Georg A, Castellano, Daniel, Silverman, Rachel Kloss, Perini, Rodolfo F, Schloss, Charles, Atkins, Michael B

Volltext

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial von Sweeney, Christopher, Bracarda, Sergio, Sternberg, Cora N, Chi, Kim N, Olmos, David, Sandhu, Shahneen, Massard, Christophe, Matsubara, Nobuaki, Alekseev, Boris, Parnis, Francis, Atduev, Vagif, Buchschacher, Gary L, Gafanov, Rustem, Corrales, Luis, Borre, Michael, Stroyakovskiy, Daniil, Alves, Gustavo Vasconcelos, Bournakis, Evangelos, Puente, Javier, Harle-Yge, Marie-Laurence, Gallo, Jorge, Chen, Geng, Hanover, Justin, Wongchenko, Matthew J, Garcia, Josep, de Bono, Johann S

Volltext

Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection von Tsimafeyeu, Ilya, Gafanov, Rustem, Protsenko, Svetlana, Semenova, Anna, Oganesyan, Ani, Nurgaliyev, Nurzhan, Krasny, Sergei, Bondarenko, Anastasia, Safina, Sufia, Zakurdaeva, Kristina

Volltext

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECH... von Lara, Jr, Primo N, Villanueva, Luis, Ibanez, Carolina, Erman, Mustafa, Lee, Jae Lyun, Heinrich, Daniel, Lipatov, Oleg Nikolaevich, Gedye, Craig, Gokmen, Erhan, Acevedo, Alejandro, Semenov, Andrey, Park, Se Hoon, Gafanov, Rustem Airatovich, Kose, Fatih, Jones, Mark, Du, Xiaoqi, Munteanu, Mihaela, Perini, Rodolfo, Choueiri, Toni K, Motzer, Robert J

Volltext

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEY... von Antonarakis, Emmanuel S, Park, Se Hoon, Goh, Jeffrey C, Shin, Sang Joon, Lee, Jae Lyun, Mehra, Niven, McDermott, Ray, Sala-Gonzalez, Núria, Fong, Peter C, Greil, Richard, Retz, Margitta, Sade, Juan Pablo, Yanez, Patricio, Huang, Yi-Hsiu, Begbie, Stephen D, Gafanov, Rustem Airatovich, De Santis, Maria, Rosenbaum, Eli, Kolinsky, Michael P, Rey, Felipe, Chiu, Kun-Yuan, Roubaud, Guilhem, Kramer, Gero, Sumitomo, Makoto, Massari, Francesco, Suzuki, Hiroyoshi, Qiu, Ping, Zhang, Jinchun, Kim, Jeri, Poehlein, Christian H, Yu, Evan Y

Volltext

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study von Plimack, Elizabeth R, Powles, Thomas, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Waddell, Tom, Alekseev, Boris, Pouliot, Frédéric, Melichar, Bohuslav, Soulières, Denis, Borchiellini, Delphine, McDermott, Raymond S, Vynnychenko, Ihor, Chang, Yen-Hwa, Tamada, Satoshi, Atkins, Michael B, Li, Chenxiang, Perini, Rodolfo, Molife, L Rhoda, Bedke, Jens, Rini, Brian I

Volltext

A phase II pilot study of the efficacy and safety of nivolumab and ipilimumab in T1aN0M0 renal cell carcinoma patients ineligible for surgical treatment von Tsimafeyeu, Ilya, Volkova, Maria, Gafanov, Rustem Airatovich, Nosov, Dmitry, Bex, Axel

Volltext

KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer von Petrylak, Daniel P, Ratta, Raffaele, Gafanov, Rustem, Facchini, Gaetano, Piulats, Josep M, Kramer, Gero, Flaig, Thomas W, Chandana, Sreenivasa R, Li, Ben, Burgents, Joseph, Fizazi, Karim

Volltext

Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma von Bedke, Jens, Rini, Brian I., Plimack, Elizabeth R., Stus, Viktor, Gafanov, Rustem, Waddell, Tom, Nosov, Dimitry, Pouliot, Frederic, Soulières, Denis, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio J., Borchiellini, Delphine, McDermott, Raymond S., Tamada, Satoshi, Nguyen, Allison Martin, Wan, Shuyan, Perini, Rodolfo F., Rhoda Molife, L., Atkins, Michael B., Powles, Thomas

Volltext

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk a... von Rini, Brian I., Plimack, Elizabeth R., Stus, Viktor, Gafanov, Rustem, Hawkins, Robert, Nosov, Dmitry, Pouliot, Frederic, Soulieres, Denis, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio Jobim, Borchiellini, Delphine, McDermott, Raymond S., Bedke, Jens, Tamada, Satoshi, Wan, Shuyan, Perini, Rodolfo F., Chen, Mei, Atkins, Michael B., Powles, Thomas

Volltext

Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur Uro... von Plimack, Elizabeth R., Powles, Thomas, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Waddell, Tom, Alekseev, Boris, Pouliot, Frédéric, Melichar, Bohuslav, Soulières, Denis, Borchiellini, Delphine, McDermott, Raymond S., Vynnychenko, Ihor, Chang, Yen-Hwa, Tamada, Satoshi, Atkins, Michael B., Li, Chenxiang, Perini, Rodolfo, Molife, L. Rhoda, Bedke, Jens, Rini, Brian I.

Volltext

First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B von McDermott, David F., Lee, Jae-Lyun, Ziobro, Marek, Gafanov, Rustem Airatovich, Matveev, Vsevolod Borisovich, Suárez, Cristina, Donskov, Frede, Pouliot, Frederic, Alekseev, Boris Y., Wiechno, Pawel, Tomczak, Piotr, Climent Duran, Miguel Angel, Shin, Sang Joon, Silverman, Rachel Kloss, Perini, Rodolfo F., Schloss, Charles, Atkins, Michael B.

Volltext

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Uro... von Plimack, Elizabeth R, Powles, Thomas, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Waddell, Tom, Alekseev, Boris, Pouliot, Frédéric, Melichar, Bohuslav, Soulières, Denis, Borchiellini, Delphine, McDermott, Raymond S, Vynnychenko, Ihor, Chang, Yen-Hwa, Tamada, Satoshi, Atkins, Michael B, Li, Chenxiang, Perini, Rodolfo, Molife, L Rhoda, Bedke, Jens, Rini, Brian I

Volltext

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426 von Rini, Brian I., Plimack, Elizabeth R., Stus, Viktor, Gafanov, Rustem, Waddell, Tom, Nosov, Dmitry, Pouliot, Frederic, Alekseev, Boris, Soulieres, Denis, Melichar, Bohuslav, Vynnychenko, Ihor O., Azevedo, Sergio Jobim, Borchiellini, Delphine, McDermott, Raymond S., Bedke, Jens, Tamada, Satoshi, Wu, Sterling, Burgents, Joseph, Molife, L. Rhoda, Powles, Thomas

Volltext

Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study von Petrylak, Daniel P., Ratta, Raffaele, Matsubara, Nobuaki, Korbenfeld, Ernesto Pablo, Gafanov, Rustem, Mourey, Loic, Todenhöfer, Tilman, Gurney, Howard, Kramer, Gero, Bergman, Andre M., Zalewski, Pawel, De Santis, Maria, Armstrong, Andrew J., Gerritsen, Winald R., Pachynski, Russell Kent, Byun, Seok-Soo, Li, Xin Tong, Schloss, Charles, Poehlein, Christian Heinrich, Fizazi, Karim

Volltext